Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

5.0K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Massive barcode-free chemical screenings enable the discovery of bioactive macrocycles with passive membrane permeability.

Nature communications·2026
Same author

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.

Blood·2025
Same author

Enhanced FLI1 accessibility mediates STAG2-mutant leukemogenesis.

bioRxiv : the preprint server for biology·2025
Same author

One for All and All for One: New Insights into Enhancers Driving MYC Dysregulation.

Blood cancer discovery·2025
Same author

Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q.

Blood cancer discovery·2025
Same author

Oncogenic Enhancers in Leukemia.

Blood cancer discovery·2024

Related Experiment Video

Updated: May 31, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.3K

Mechanisms of enhancer-driven oncogene activation.

Joyce Vriend1,2, Ruud Delwel1,2, Dorien Pastoors1,2

  • 1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

International Journal of Cancer
|January 24, 2025
PubMed
Summary

Enhancer hijacking causes aggressive acute myeloid leukemia (AML) by increasing MECOM expression. Understanding enhancer deregulation is key to developing new AML treatments.

Keywords:
AMLenhancer hijackingleukemiaoncogene activation

More Related Videos

AAV Deployment of Enhancer-Based Expression Constructs In Vivo in Mouse Brain
09:59

AAV Deployment of Enhancer-Based Expression Constructs In Vivo in Mouse Brain

Published on: March 31, 2022

2.6K
Author Spotlight: An Integrated Workflow to Study the Promoter-Centric Spatio-Temporal Genome Architecture in Scarce Cell Populations
11:36

Author Spotlight: An Integrated Workflow to Study the Promoter-Centric Spatio-Temporal Genome Architecture in Scarce Cell Populations

Published on: April 21, 2023

1.9K

Related Experiment Videos

Last Updated: May 31, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.3K
AAV Deployment of Enhancer-Based Expression Constructs In Vivo in Mouse Brain
09:59

AAV Deployment of Enhancer-Based Expression Constructs In Vivo in Mouse Brain

Published on: March 31, 2022

2.6K
Author Spotlight: An Integrated Workflow to Study the Promoter-Centric Spatio-Temporal Genome Architecture in Scarce Cell Populations
11:36

Author Spotlight: An Integrated Workflow to Study the Promoter-Centric Spatio-Temporal Genome Architecture in Scarce Cell Populations

Published on: April 21, 2023

1.9K

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Aggressive acute myeloid leukemia (AML) subtypes are driven by enhancer hijacking, leading to MECOM overexpression.
  • Chromosomal rearrangements like inv(3)/t(3;3) hijack the GATA2 enhancer, while other rearrangements involve different hematopoietic gene enhancers.
  • BCL11B can hijack the same enhancers as MECOM, indicating broader roles for enhancer deregulation.

Purpose of the Study:

  • To investigate the mechanisms of enhancer deregulation in AML.
  • To explore the role of super-enhancers in oncogenesis.
  • To identify potential therapeutic targets for AML and other cancers driven by enhancer deregulation.

Main Methods:

  • Analysis of chromosomal rearrangements in AML.
  • Investigation of enhancer activity and gene expression.
  • Study of TAD boundary disruptions and de novo super-enhancer formation.

Main Results:

  • Identified enhancer hijacking as a cause of MECOM overexpression in AML.
  • Demonstrated that enhancers hijacked by MECOM can also be hijacked by BCL11B.
  • Proposed that TAD boundary disruptions and super-enhancers may drive oncogenesis in AML without translocation-mediated enhancer hijacking.

Conclusions:

  • Enhancer deregulation is a significant driver of oncogenesis in AML and other malignancies.
  • Mechanistic insights into enhancer deregulation and super-enhancer activity are crucial for developing novel cancer therapies.
  • Targeting enhancer deregulation offers a promising avenue for treating AML and related cancers.